Download PDF
Pharmacopsychiatry 2001; 34(6): 223-231
DOI: 10.1055/s-2001-18034
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Endocrine and Metabolic Abnormalities Involved in Obesity
Associated with Typical Antipsychotic Drug Administration

T. Baptista1 , A. Lacruz1 , F. Angeles2 , R. Silvera2 , S. de Mendoza3 , M.  T. Mendoza4 , L. Hernández1
  • 1Department of Physiology, Los Andes University Medical School, Merida, Venezuela
  • 2Department of Psychiatry, Los Andes University Medical School, Merida, Venezuela
  • 3Metabolism Center, Merida, Venezuela
  • 4Santiago de Leon Clinic, Nirgua, Carabobo, Venezuela
Further Information

Publication History

Publication Date:
26 October 2001 (online)

Also available at
    Permissions and Reprints

In this study, the authors assessed the endocrine system and glucose tolerance in obese and non-obese women chronically treated with typical antipsychotic drugs (AP). In particular, we tested the hypotheses that these subjects display hypogonadism and increased insulin resistance compared to healthy weight-matched controls, as these abnormalities create a tendency towards excessive body weight gain. Twenty-six AP-treated women were matched with 26 healthy women by age, body mass index and day of the menstrual cycle. The following serum variables were evaluated in each subject: glucose tolerance after an oral glucose overload, insulin, leptin, β-endorphin, reproductive hormones, adrenal steroids and lipids. Compared to controls, AP-treated women displayed significantly higher levels of basal glucose, insulin after 60 min of the glucose overload, prolactin, thyroid stimulating hormone and β-endorphin, with lower levels of C-Peptide, progesterone, 17-OH progesterone, androstenedione and high-density lipoprotein cholesterol. The levels of estradiol, estrone and leptin did not differ between the groups. Thus, women treated with typical AP appeared to display more insulin resistance than healthy controls, predisposing them to excessive weight gain. Insulin sensitivity might be further impaired when the subject switches to atypical AP administration. Metformin and related agents may reduce body weight in these subjects. The high levels of the opiate β-endorphin suggest that opiate antagonists such as naloxone and naltrexone might be useful as well. Even though the luteal phase of the menstrual cycle appears to be severely disturbed, the normal serum levels of estradiol and estrone do not support the proposal derived from animal experimental studies about the use of estrogens or tamoxifen to counteract AP-induced obesity.

References

  • 1 Allison D B, Mentore J L, Heo M, Chandler LP, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
    PubMedGoogle Scholar
  • 2 Allison D B, Fontaine K R, Heo M, Mentore J L, Cappelleri J C, Chandler L P, Weiden P J, Cheskin L J. The distribution of body mass index among individuals with and without schizophrenia.  J Clin Psychiatry. 1999;  60 215-220
    PubMedGoogle Scholar
  • 3 Ammon H PT, Orci I, Steinke J. Effect of chlorpromazine on insulin release in vivo and in vitro in the rat.  J Pharmacol Exp Ther. 1973;  187 423-429
    PubMedGoogle Scholar
  • 4 Ataya K, Mercado A, Kartaginer J, Abbasi J, Moghissi K S. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia.  Fertil & Steril. 1988;  50 876-881
    PubMedGoogle Scholar
  • 5 Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management.  Acta Psychiat Scand. 1999;  100 3-16
    PubMedGoogle Scholar
  • 6 Baptista T, Parada M A, Herna¿ndez L. Long-term administration of some antipsychotic drugs increases body weight and feeding in rats: Are D2 dopamine receptors involved?.  Pharmacol Biochem Behav. 1987;  27 399-405
    CrossrefPubMedGoogle Scholar
  • 7 Baptista T, Alastre T, Contreras Q, Martinez J L, Araujo de Baptista E, Pa¿ez X, Herna¿ndez L. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation.  Pharmacopsychiat. 1997;  30 250-255
    PubMedGoogle Scholar
  • 8 Baptista T, Molina M G, de Quijada M, Calanche I, Acosta A, Pa¿ez X, Martinez J L, Martinez J M, Herna¿ndez L. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy women: relationship with body weight regulation.  Pharmacopsychiatry. 1997;  30 256-262
    PubMedGoogle Scholar
  • 9 Baptista T, Araujo de Baptista E, Altemus M, Weiss S RB, Teneud L, Herna¿ndez L. Tamoxifen prevents sulpiride-induced obesity in rats.  Pharmacol Biochem Behav. 1997;  57 215-222
    CrossrefPubMedGoogle Scholar
  • 10 Baptista T, Reyes D, Hernández L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation.  Pharmacol Biochem Behav. 1999;  62 409-417
    CrossrefPubMedGoogle Scholar
  • 11 Baptista T, Lacruz A, Acosta A, Colasante C, de Quijada M, de Mendoza S, Mendoza J M, Hernandez L. Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats.  Appetite. 2000;  34 77-86
    CrossrefPubMedGoogle Scholar
  • 12 Baptista T, Lacruz A, Silvera R, Angeles F, Mendoza S, Mendoza J M, Mendoza M T, Herna¿ndez L. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones.  Pharmacopsychiat. 2000;  33 81-88
    PubMedGoogle Scholar
  • 13 Beumont P JV, Gelder M G, Friesen H G, Harris G W, MacKinnin P CB, Mandelbrote B M, Wiles D H. The effects of phenothiazines on endocrine function: I: patients with inappropriate lactation and amenorrhoea.  Brit J Psychiatry. 1974;  124 413-419
    PubMedGoogle Scholar
  • 14 Beumont P JV, Corker C S, Friesen H G, Kolakowska T, Mandelbrote B M, Marshall J, Murray M AF, Wiles D H. The effects of phenothiazines on endocrine function: II: effects in men and post-menopausal women.  Brit J Psychiatry. 1974;  124 420-430
    PubMedGoogle Scholar
  • 15 Brambilla F, Guastalla A, Guerini A, Riggi F, Rovere C, Zanoboni A, Zanoboni-Muciaccia W. Glucose-insulin metabolism in chronic schizophrenia.  Dis Nerv Sys. 1976;  37 98-103
    PubMedGoogle Scholar
  • 16 Bromel T, Blum W F, Zeigler A, Schulz W, Bender M, Fleisbacher C, Remmsschmidth H, Krieg J C, Heberbrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy.  Mol Psychiat. 1998;  3 76-80
    PubMedGoogle Scholar
  • 17 Cabrera R, Mayor P, Ferna¿ndez-Ruiz J, Calle C. Insulin binding and action on adipocytes from female rats with experimentally-induced chronic hyperprolactinemia.  Mol Cell Endocrinol. 1988;  58 167-173
    CrossrefPubMedGoogle Scholar
  • 18 Correa N, Opler L A, Kay S R, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics.  J Clin Psychopharmacol. 1987;  7 91-95
    PubMedGoogle Scholar
  • 19 Crawford A MK, Beasley C HM, Tollefson G D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration.  Schizophr Res. 1997;  26 41-54
    PubMedGoogle Scholar
  • 20 Dixon L, Weiden P, Delahanty J, Goldberg R, Postgrado L, Lucksted A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples.  Schizophr Bull. 2000;  26 903-912
    CrossrefPubMedGoogle Scholar
  • 21 Dorrington J, Gore-Langton I. Prolactin inhibits oestrogen synthesis in the ovary.  Nature. 1981;  290 600-602
    CrossrefPubMedGoogle Scholar
  • 22 Eckel R H. Insulin resistance: an adaptation for weight maintenance.  Lancet. 1992;  340 1452-1453
    CrossrefPubMedGoogle Scholar
  • 23 Erhardt V R, Goldman M B. Adverse Endocrine Effects. In: Keshavan MS, Kennedy JS, editors Drug-Induced Dysfunction in Psychiatry. New York; Hemisphere Publishing Corporation 1992: 296-297
    Google Scholar
  • 24 Erle G, Basso M, Federspil G, Sicolo N, Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man.  Eur J Clin Pharmacol. 1977;  11 15-18
    CrossrefPubMedGoogle Scholar
  • 25 Ferreira M F, Sobrinho L G, Santos M A, Sousa M F, Uvnas-Mogberg K. Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone.  Psychoneuroendocrinol. 1998;  23 1005-1013
    PubMedGoogle Scholar
  • 26 Fontbonne A, Charles M A, Juhan Vague I, Bard J M, Andre¿ P, Isnard F, Cohen J M, Granmottet P, Vague P, Safer M E, Eschwege E. The effects of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.  Diabetes Care. 1996;  19 920-926
    PubMedGoogle Scholar
  • 27 Foss M C, Paula F J, Paccola G M, Piccinato C E. Peripheral glucose metabolism in human hyperprolactinemia.  Clin Endocrinol. 1995;  43 721-726
    CrossrefPubMedGoogle Scholar
  • 28 Genazzani A R, Facchinetti F, Petraglia F, Pintor C, Corda R. Hyperendorphinemia in obese children and adolescents.  J Clin Endocrinol Metab. 1986;  62 36-40
    PubMedGoogle Scholar
  • 29 Gerardo-Gettens T, Moore B J, Stern J S, Horwitz B A. Prolactin stimulates food intake in a dose-dependent manner.  Am J Physiol. 1989;  256 R276-R280
    PubMedGoogle Scholar
  • 30 Giusti G, Bassi F, Forti G. Effects of prolactin on androgens secretion by the human adrenal cortex. In: Harter RC, editors Progress in Prolactin Physiology and Pathology. Amsterdam; Elsevier 1978
    Google Scholar
  • 31 Givens J R. Reproductive and hormonal alterations in obesity. In: Bjorntorp P, Brodoff BN, eds. Obesity. Philadelphia; J. B. Lippincott Company 1992: 540-550
    Google Scholar
  • 32 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.  Clin Endocrinol. 1998;  48 547-553
    CrossrefPubMedGoogle Scholar
  • 33 Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial on the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.  Br J Psychiatry. 1988;  153 208-213
    PubMedGoogle Scholar
  • 34 Gopalaswamy A K, Morgan R. Too many chronic mentally disabled patients are too fat.  Acta Psychiat Scand. 1985;  72 254-258
    PubMedGoogle Scholar
  • 35 Green A I, Patel J K, Goisman R M, Allison D B, Blackburn G. Weight gain from novel antipsychotic drugs: need for action.  Gen Hosp Psychiat. 2000;  22 224-235
    PubMedGoogle Scholar
  • 36 Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlquvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.  J Clin Psychiatry. 1998;  59 294-299
    PubMedGoogle Scholar
  • 37 Hartman D S, Civelli O. Molecular attributes of dopamine receptors: new potential for antipsychotic drug development.  Ann Med. 1996;  28 211-219
    PubMedGoogle Scholar
  • 38 Kissebah A H, Krakower G R. Regional adiposity and morbidity.  Physiol Rev. 1994;  74 761-811
    PubMedGoogle Scholar
  • 39 Kopelman P G. Obesity as a medical problem.  Nature. 2000;  404 635-643
    CrossrefPubMedGoogle Scholar
  • 40 Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs.  Am J Psychiat. 1999;  156 314-321
    PubMedGoogle Scholar
  • 41 Lacruz A, Baptista T, de Mendoza S, Mendoza-Guillén J M, Hernández L. Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment.  Mol Psychiat. 2000;  5 70-76
    PubMedGoogle Scholar
  • 42 Leibowitz S F, Hoebel B G. Behavioral Neuroscience of Obesity. In: Bray GA, Bouchard C, James WPT, eds. Handbook of Obesity. New York; Marcel Dekker, Inc 1998: 313-358
    Google Scholar
  • 43 Lobo R, Kletzky O. Normalization of androgen and sex hormone binding globulin levels after treatment of hyperprolactinemia.  J Clin Endocrinol Metab. 1982;  56 562-568
    PubMedGoogle Scholar
  • 44 MacNatty K P, Sawers R S, McNeilly A S. A possible role for prolactin in control of steroid secretion by the human Graafian follicle.  Nature. 1975;  250 653-655
    PubMedGoogle Scholar
  • 45 Matsuda M, Mori T. Effect of estrogen on hyperprolactinemia-induced glucose intolerance in SHN mice.  Proc Soc Exp Biol Med. 1996;  212 243-247
    PubMedGoogle Scholar
  • 46 Matsuzaki T, Azuma K, Irahara M, Yasui T, Aono T. Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin.  Fertil Steril. 1994;  62 1143-1149
    CrossrefPubMedGoogle Scholar
  • 47 Melkerson K I, Hulting A L, Brismar K E. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.  J Clin Psychiatry. 1999;  60 783-791
    PubMedGoogle Scholar
  • 48 Melkerson K I, Hulting A L, Brismar K E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.  J Clin Psychiatry. 2000;  61 742-749
    PubMedGoogle Scholar
  • 49 Meltzer H Y, Goode D, Schyve P M, Young M, Fang V. Effect of clozapine on human serum prolactin levels.  Am J Psychiatry. 1979;  136 1550-1555
    PubMedGoogle Scholar
  • 50 Moore B J, Gerardo-Gettens T, Horwitz B A, Stern J S. Hyperprolactinemia stimulates food intake in the female rat.  Brain Res Bull. 1986;  17 563-569
    CrossrefPubMedGoogle Scholar
  • 51 Murialdo G, Galimberti C A, Gianelli M V, Rollero A, Polleri A, Copello F, Magri F, Ferrari E, Sampaolo P, Manni R, Tartara A. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy.  Clin Neuropharmacol. 1998;  21 52-58
    PubMedGoogle Scholar
  • 52 Oades R D, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients.  Psychoneuroendocrinology. 1994;  19 373-385
    PubMedGoogle Scholar
  • 53 Parada M A, Herna¿ndez L, Pa¿ez X, Baptista T, Puig de Parada M, Quijada M. Mechanism of the sulpiride-induced obesity in rats.  Pharmacol Biochem Behav. 1989;  33 45-50
    CrossrefPubMedGoogle Scholar
  • 54 Paykel E S, Mueller P S, De La Vergne P M. Amitryptiline, weight gain and carbohydrate craving: a side effect.  Brit J Psychiat. 1973;  123 501-507
    PubMedGoogle Scholar
  • 55 Peiris A, Kissebah A. Endocrine abnormalities in morbid obesity.  Gastroenterol Clin N Amer. 1987;  16 389-398
    PubMedGoogle Scholar
  • 56 Percheron C, Colette C, Mariano-Goulart D, Avignon A, Capeyron O, Boniface H, Bressot N, Monnier L. Relationship between insulin sensitivity, obesity, body fat distribution and beta-endorphinemia in obese women.  Int J Obes Relat Metab Disord. 1998;  22 143-148
    CrossrefPubMedGoogle Scholar
  • 57 Poretsky L, Cartin M F. The gonadotropic function of insulin.  Endocrinol Rev. 1987;  8 132-136
    PubMedGoogle Scholar
  • 58 Ravussin E. Metabolic differences and the development of obesity.  Metabolism. 1995;  44 12-14
    PubMedGoogle Scholar
  • 59 Reiss F M, Ribeiro de Oliveira J R, Guerra R M, Reiss A M, Coimbra C C. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress.  Life Sci. 1996;  58 155-161
    PubMedGoogle Scholar
  • 60 Rinieris P, Markianos M, Hatzimanolis J, Stefanis C. A psychoendocrine study in male paranoid schizophrenic patients with delusional ideas of homosexual content.  Acta Psychiatr Scand. 1985;  3 309-314
    PubMedGoogle Scholar
  • 61 Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vitro.  Diabetol. 1985;  28 138-142
    PubMedGoogle Scholar
  • 62 Schimmelbusch W H, Mueller P S, Sheps J. The positive correlation between insulin resistance and duration of hospitalization in untreated schizophrenia.  Brit J Psychiatry. 1971;  118 429-436
    PubMedGoogle Scholar
  • 63 Schultz S K, Arndt S, Ho B C, Oliver S E, Andreasen N C. Impaired glucose tolerance and abnormal movements in patients with schizophrenia.  Am J Psychiatry. 1999;  156 640-642
    PubMedGoogle Scholar
  • 64 Schwartz M W, Woods S C, Porte D, Seeley R J, Baskin D G. Central nervous system control of food intake.  Nature. 2000;  404 661-671
    CrossrefPubMedGoogle Scholar
  • 65 Serri O, Beauregard H, Rasio E, Hardy J. Decreased sensitivity to insulin in women with microprolactinomas.  Fertil Steril. 1986;  45 572-574
    PubMedGoogle Scholar
  • 66 Silverstone T, Finchman J, Wells B, Kyriakides M. The effect of the dopamine receptor-blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man.  Neuropharmacology. 1980;  19 1235-1237
    CrossrefPubMedGoogle Scholar
  • 67 Sletten I W, Gershon S. The effect of chlorpromazine on water and electrolyte balance.  J Nerv Ment Dis. 1966;  142 25-31
    PubMedGoogle Scholar
  • 68 Sociedad Venezolana de Cardiología . Recomendaciones de ILIB para el diagnóstico y tratamiento de las dislipidemias en Latinoamérica.  Avances Cardiología. 1994;  XIV ( Suppl. 1) 12-15
    PubMedGoogle Scholar
  • 69 Stanton J M. Weight gain associated with neuroleptic medication: a review.  Schiz Bull. 1995;  21 463-472
    PubMedGoogle Scholar
  • 70 Taylor D M, Mcaskill R. Atypical antipsychotics and weight gain - a systematic review.  Acta Psychiat Scand. 2000;  101 416-432
    PubMedGoogle Scholar
  • 71 Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, Kubo K, Momotami Y, Sanke T, Nanjo K. Characteristics of diabetes melitus in schizophrenic patients.  J Med Assoc Thai. 1987;  70 (Suppl 2) 90-93
    PubMedGoogle Scholar
  • 72 Vaccarino F J, Mogil J S, Stinus L. Chronic dopamine antagonism facilitates opiate-induced feeding.  J Psychiat Neurosci. 1995;  20 210-214
    PubMedGoogle Scholar
  • 73 Velasquez E, Mendoza S, Harner T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.  Metabolism. 1994;  5 647-654
    PubMedGoogle Scholar
  • 74 Wade G N, Schneider J E. Metabolic fuels and reproduction in female mammals.  Neurosci Biobehav Rev. 1992;  16 235-272
    CrossrefPubMedGoogle Scholar
  • 75 Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat.  Nature. 1998;  393 684-688
    CrossrefPubMedGoogle Scholar
  • 76 West J B. Physiological Basis of Medical Practice, 12th Edition. Baltimore; Williams & Wilkins 1991: Chap. 53
    Google Scholar
  • 77 Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C. Novel antipsychotics and new onset diabetes.  Biol Psychiatry. 1998;  44 778-783
    CrossrefPubMedGoogle Scholar
  • 78 Wirshing D A, Wirshing W C, Kysar L, Berisford M A, Goldstein D, Pashdag J, Mintz J, Marder S R. Novel antipsychotics: comparison of weight gain liabilities.  J Clin Psychiatry. 1999;  60 358-363
    CrossrefPubMedGoogle Scholar
  • 79 Woods S C, Seeley R J, Porte D, Schwartz M W. Signals that regulate food intake and energy homeostasis.  Science. 1998;  280 1378-1382
    CrossrefPubMedGoogle Scholar
  • 80 Yazici K M, Erbas T, Yazici A H. The effect of clozapine on glucose metabolism.  Exp Clin Endocrinol Diabetes. 1998;  106 475-477
    PubMedGoogle Scholar
  • 81 Zimmermann U, Rechlin T H, Plaskacewicz G J, Barocka A, Wildt L, Kaschka P. Effect of Naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study.  Biol Psychiat. 1997;  41 747-749
    PubMedGoogle Scholar

Trino BaptistaM.D. 

Douglas Hospital Research Center (F1116)

6875 Lasalle Blvd

Verdun

Quebec, Canada H4H 1R3

Phone: (514) 761 61 31 ext. 34 52

Fax: (514) 888 40 64

Email: baptri@douglas.mcgill.ca